No Data
No Data
Express News | Bristol-Myers Squibb - Safety Profile for Opdivo Plus Yervoy Was Consistent With Prior Findings, With No New Safety Signals Observed
Express News | Bristol-Myers Squibb Co - at Ten Years, More Than 40% of Patients Treated With Opdivo Plus Yervoy Were Alive
Express News | Bristol Myers Squibb Presents Landmark 10-Year Follow-up Data From Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit With Opdivo® Plus Yervoy® in Advanced Melanoma
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
Bristol-Myers Squibb's KarXT Faces FDA Approval Hurdles: Analyst Issues Sell Rating Amid Labeling Concerns
Bicara, MBX Bio Lead Gainers as Biotech Trio Makes Trading Debut
No Data
No Data